Vivani Medical Flags Going Concern, Cash Runs Out by Q2 2027
VANI sits 45% above its 52-week low of $0.923.
Summary
Vivani Medical's Q2 2026 10-Q discloses a going concern warning with cash runway only through Q2 2027, exhausted equity financing agreements, and quantified terms for the Cortigent-ClearOne merger.
Key Events · Earnings and Guidance · VANI
-
Going Concern Warning
Management states existing cash funds operations only through Q2 2027, raising substantial doubt about the company's ability to continue as a going concern within one year.
-
Financing Exhausted
The final tranche of the 2025 Private Sales Transactions closed July 15, 2026, exhausting all $21.2 million in equity purchase agreements with no further proceeds available.
-
Cortigent Merger Terms Quantified
Vivani will receive 12,500,000 ClearOne shares for all Cortigent stock, expected to become majority owner of the combined company; ClearOne pursuing $10-15 million concurrent financing.
-
SLIM-1 Topline Data November 2026
Dosing completed for all 20 participants in the SLIM-1 Phase 1 trial of NPM-139 semaglutide implant; topline data anticipated November 2026.
Analysis · VANI · Industrial Applications And Services
Vivani Medical's Q2 2026 10-Q reveals the company has only enough cash to fund operations through the second quarter of 2027, raising substantial doubt about its ability to continue as a going concern. The company exhausted its $21.2 million in equity purchase agreements with the final tranche closing on July 15, 2026, and now must rely on the Cortigent merger with ClearOne and additional capital raises to survive. The merger consideration is quantified at 12.5 million ClearOne shares, with Vivani expected to become majority owner of the combined company. SLIM-1 topline data for the NPM-139 semaglutide implant is anticipated in November 2026, a key upcoming milestone.
At the time of this filing, VANI was trading at $1.34 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $115.6M. The 52-week trading range was $0.92 to $1.92. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.